NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CPI Card Group Inc. (“CPI” or the “Company”) (NASDAQ: PMTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CPI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 8, 2025, CP ...

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Barnes & Noble Education, Inc. (“Barnes & Noble” or the “Company”) (NYSE: BNED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Barnes & Noble and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the clas ...

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On July 22, 2025, Telix disclosed that it received a subpoena from the U.S. Securities and Exchange Commission, which is seeking various documents and information related to the company's disclosures about its prostate cancer therapeutic candidates [2]. - Following the news of the subpoena, Telix's American Depositary Receipt (ADR) price fell by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Barnes & Noble Education, Inc. is under investigation for potential securities fraud and unlawful business practices, which has led to a significant drop in its stock price following the announcement of a delay in its annual report due to accounting issues [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud by Barnes & Noble and its officers or directors [1]. - The investigation is focused on how the costs of digital sales were recorded, with early findings suggesting that accounts receivable may have been overstated by up to $23 million [3]. Group 2: Financial Impact - Following the announcement of the investigation and the delay in the annual report, Barnes & Noble's stock price fell by $2.36 per share, representing a 21.02% decrease, closing at $8.87 per share on July 21, 2025 [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving WPP plc and its officers or directors [1] Financial Performance - On July 8, 2025, WPP reduced its 2025 guidance for like-for-like revenue less pass-through costs to a decline of 3% to 5% and anticipated a year-on-year decline in headline operating profit margin of 50 to 175 basis points, excluding foreign exchange effects [3] - WPP reported a deterioration in performance as the second quarter progressed, attributing this to a challenging economic backdrop and expected continued macro uncertainty affecting client spending and weaker net new business than initially anticipated [3] - Following the announcement, WPP's American Depositary Receipt (ADR) price fell by $6.48, or 18.09%, closing at $29.34 per ADR on July 9, 2025 [3]

Group 1 - The investigation by Pomerantz LLP concerns potential securities fraud or unlawful business practices by Vera Bradley and its officers or directors [1] - Vera Bradley reported disappointing financial results for Q1 of fiscal year 2026, with CEO Jackie Ardrey acknowledging the need for significant improvements to achieve positive growth [3] - Following the announcement of poor financial results, Vera Bradley's stock price dropped by $0.45, or 19.15%, closing at $1.90 per share on June 11, 2025 [4] Group 2 - Vera Bradley announced key leadership changes, including the departure of CEO Jackie Ardrey at the end of July 2025 [3]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Globus Medical reported financial results for Q1 2025, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, which was $27.78 million below expectations and represented a 1.4% year-over-year decline [3] - Following the disappointing financial results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q1 2025 were reported at $0.68, missing estimates by $0.06 [3] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and showing a 1.4% decline compared to the previous year [3] - The decline in performance was attributed to softer deal closures, supply chain disruptions, and timing issues with international distributor orders [3] Stock Market Reaction - The stock price of Globus Medical experienced a significant drop of $16.64 per share, equating to a 22.96% decrease [3] - The closing price after the drop was $55.82 per share on May 9, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Redwire Corporation and its officers or directors [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which missed consensus estimates by $13.14 million and marked a 30.1% year-over-year decline [3] - The company attributed the revenue decline to delays in U.S. government contract awards due to leadership transitions at agencies like NASA and the Space Development Agency, as well as shifting budget priorities under the Trump administration [3] Stock Market Reaction - Following the financial results announcement, Redwire's stock price decreased by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a Phase 3 second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives, following disappointing financial results and stock price decline [1][3]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which was $13.14 million below consensus estimates, marking a 30.1% decline year-over-year [3]. - The company attributed the revenue shortfall to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the release of the financial results, Redwire's stock price decreased by $0.75, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].